Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
search results for:
dealforma
Search
Decades after breakthrough, scientists still puzzling over mRNA delivery
3 years ago
R&D
In Focus
Top 100 biotech venture investors; Bristol Myers’ IL-12 breakup; Scientific twist of fate; Tracking biopharma ...
3 years ago
Weekly
The top 100 venture investors in biopharma today. Who's staying at the deals table?
3 years ago
Deals
Bioregnum
How Purdue's $272M addiction payout funded a new home for its discarded non-opioid research
3 years ago
Pharma
In Focus
In its largest single-asset purchase ever, Takeda snaps up TYK2 drug for $4B upfront
3 years ago
Deals
As money pours into digital therapeutics, insurance coverage crawls
3 years ago
R&D
In Focus
A rare biotech IPO lands on Nasdaq, boosted by RA Capital and a former Eli Lilly drug
3 years ago
Financing
Biogen, Seagen lock in CEOs; 2022 so far — by the numbers; Pharma on Twitter; Wave of biotech downsizing ; and more
3 years ago
Weekly
By the numbers: As the pandemic biotech boom fades, it's beginning to look a lot like 2019 — or before
3 years ago
Deals
Will feds reclassify 'magic mushroom' therapies? Seattle doctor ramps up court battle
3 years ago
Pharma
Law
Biotech’s downturn fuels a billionaire’s niche investment industry
3 years ago
R&D
In Focus
Previewing biopharma trends ahead of #BIO22; Looking back at #ASCO22; Smooth flight for bluebird?; and more
4 years ago
Weekly
#BIO22: By the Numbers: After the music died, you can see some encouraging signs on the M&A and licensing fronts. But ...
4 years ago
Deals
Biotech’s biggest investor is prepping a whopping $4.75B wager on the future of the industry
4 years ago
Deals
Latest news on ‘devastating’ AbbVie drug discontinuation; Biogen's worst case scenario; Finally, some M&A; and ...
4 years ago
Weekly
The good, the bad and lots of just plain old ugly: The Q1 numbers are in
4 years ago
Inside the race to make psychedelics 'mainstream medicines'
4 years ago
R&D
In Focus
Biopharma has hyped AI for years. But as the first trials get underway, experts try to manage expectations
4 years ago
AI
In Focus
First page
Previous page
1
2
3
4
5
6
Next page
Last page
latest
Most read
Trump's tax cut law expands orphan drug exclusions, could upend 340B program
10 hours ago
Pharma
Law
Novartis maps launch of malaria drug for newborns after Swiss approval
2 minutes ago
Pharma
Clinician groups sue RFK Jr. and HHS over Covid-19 vaccine recommendation changes
9 hours ago
R&D
Pharma
The Supreme Court passed on a state PBM case. Lawyers say a broader legal fight is brewing
10 hours ago
Pharma
Law
see latest stream
